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Abstract
Introduction: Acute lymphocytic leukemia is a type of cancer most common in children and it is 
characterized by excessive and disordered immature leukocytes in the bone marrow.
Aim: Identify most frequent oral manifestations in children with acute lymphocytic leukemia 
under chemotherapy treatment. 
Methodology: The research was conducted on the eletronic database PubMed/Medline, Science 
Direct, Scielo and Scopus. It has been sought papers with full presentation, wrote in Portuguese, 
English and Spanish, published between January 1992 and April 2013. 
Results: From studies primarily selected, only eight met the criteria of inclusion. All studies per-
formed intraoral examinations to diagnose oral lesions. According to results, the most frequent 
lesions were mucositis, candidiasis, periodontitis and gingivitis. The oral health condition from 
acute lymphocytic leukemia carriers varied according oral hygiene of the patient.
Conclusion: The results of studies identified such a great part of patients with ALL presented 
some lesion in oral cavity during or after chemotherapy treatment. The dentist surgeon needs to 
recognize oral manifestations and intervene in the oral health of patients with ALL, contributing 
and helping with treatment.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier 
Editora Ltda. All rights reserved.
 
Manifestações orais decorrentes da quimioterapia em crianças portadoras de leucemia 
linfocítica aguda
Resumo
Introdução: A leucemia linfocítica aguda é um dos tipos de câncer mais comuns em crianças e é 
caracterizada pela produção excessiva e desordenada de leucócitos imaturos na medula óssea.
Objetivo: Identificar as manifestações orais mais frequentes em crianças portadoras de leuce-
mia linfocítica aguda sob o tratamento quimioterápico.
Metodologia: A pesquisa foi realizada nas bases de dados eletrônicas PubMed/Medline, Science 
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Introduction
Leukemia is a disease characterized by progressive and ex-
cessive production of leukocytes in the bone marrow, whose 
immature forms start circulating in blood.1,2 The dissemi-
nated proliferation of blasts leads to a substitution of nor-
mal bone marrow elements, resulting in the accumulation 
of immature cells in the blood. The etiology of leukemia 
is still uncertain, but many studies point to causal factors 
such as viral infection and radiation and chemical exposure. 
There are three different subtypes of lymphocytes, and thus 
there are different types of leukemia, which are classified 
according to the cell involved, as well as the duration and 
characteristics of the disease.1-4 
Acute lymphoblastic leukemia (ALL) represents approx-
imately 80% of leukemias, and occurs mostly in children.1 
ALL results in uncontrolled and excessive production of lym-
phoid blasts, hindering the normal production of red and 
white cells, as well as platelets. The chances of survival 
have increased with advances in anticancer treatment mo-
dalities.2,3
The first signs of leukemia can regularly occur in the oral 
cavity, especially in the acute phase of cancer, as common le-
sions at this stage of the disease that can be observed and 
recognized primarily by the dentist.4,5 The most common man-
ifestations of leukemia in the oral cavity are gingival bleeding, 
hyperplasia, opportunistic infections, and bone alterations. 
During the antineoplastic treatment, the lesions become 
even more severe, since chemotherapy acts on poorly dif-
ferentiated or high-metabolism cells, affecting not only 
blast cells, but also normal body cells.3,4 
The dentist needs to be aware of lesions caused by leu-
kemia and the anticancer treatment in order to improve 
the patient’s oral health. Thus, this study aimed to per-
form a systematic review of the literature on oral compli-
cations secondary to chemotherapy performed in children 
with ALL. 
Methods
A systematic search of articles in English, Portuguese, and 
Spanish published between January of 1992 and April of 
2013 was performed in the PubMed/MEDLINE, Science Di-
rect, Scopus, and SciELO databases. Studies whose the tar-
get population was children aged 2 to 18 years with ALL and 
that evaluated the complications of anticancer treatment 
in the oral cavity were selected. 
The search used the following terms: oral manifesta-
tions, Leukemia, Acute Lymphoblastic Leukemia, ALL, che-
motherapy, and children, as well as the corresponding words 
in Portuguese and Spanish. The Boolean operators AND, OR, 
NOT were used in the databases, when possible. The search 
strategies are shown in Table 1.
Direct, Scielo e Scopus. Procurou-se por artigos apresentados na íntegra, escritos em português, 
inglês e espanhol, publicados entre janeiro de 1992 e abril de 2013.
Resultados: Dos estudos selecionados primariamente, apenas oito atenderam aos critérios de 
inclusão. A população avaliada foi um grupo de crianças portadoras de leucemia linfócitica 
aguda. Todos os estudos realizaram exames intraorais para o diagnóstico das lesões bucais. 
De acordo com os resultados, as lesões mais frequentes foram mucosite, candidíase, periodon-
tite e gengivite. A condição de saúde bucal dos portadores de leucemia linfócitica aguda variou 
de acordo com a higiene bucal do paciente.
Conclusão: Pacientes com LLA podem apresentar alguma lesão na cavidade oral durante ou após 
o início da quimioterapia. O cirurgião dentista necessita reconhecer as manifestações orais e 
intervir na saúde bucal do paciente com LLA, contribuindo e auxiliando no seu tratamento.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier 
Editora Ltda. Todos os direitos reservados.
Table 1 Search strategies and number of articles found in the databases.
Strategies A B C D
(Oral Lesions OR Oral Manifestation OR Mouth Lesion OR Mouth 
Manifestation OR Oral Pathology) AND Leukemia AND Chemotherapy  
AND Children
0 88 32 801
(Oral Lesions OR Oral Manifestation OR Mouth Lesion OR Mouth 
Manifestation OR Oral Pathology) AND Acute lymphocytic leukemia  
AND Chemotherapy AND Children
0 37  0 128
(Oral Lesions OR Oral Manifestation OR Mouth Lesion OR Mouth 
Manifestation OR Oral Pathology) AND Acute lymphocytic leukemia  
AND (Chemotherapy OR antineoplastic agents) AND Children
0 34  1 134
A, Scielo; B, Science Direct; C, Scopus; D, PubMed/Medline.
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After the initial search and retrieval of abstracts, four 
independent evaluators selected the relevant studies ac-
cording to the inclusion and exclusion criteria. Longitudinal 
or cross-sectional controlled clinical trials that assessed oral 
manifestations in children with ALL were included in the sys-
tematic review. Studies in languages other than those primar-
ily chosen, in vitro studies, animal studies, literature reviews, 
case reports, and studies not associated with the target popu-
lation or the oral manifestations of the disease were excluded.
The first step in study selection was performed by an-
alyzing the titles and abstracts. Subsequently, all studies 
whose titles or abstracts were considered relevant were ob-
tained in full and thoroughly analyzed. Finally, the articles 
reviewed and selected through consensus of the five evalua-
tors were included in the data systematization. 
Results
Among the initially selected studies, 18 showed potential 
to be included in the systematic review; however, after 
thorough analysis of the studies, only eight met all the in-
clusion criteria. Among the selected studies, five had been 
performed in developing countries and three in developed 
countries; the methods and results of the studies are sum-
marized in Tables 2 and 3.
Regarding the profile of the studies, the sample size 
ranged between 17 and 156 children, with a total sample 
size of 472 children aged 2 to 18 years. The selected studies 
were published between the years 1992 and 2012. Of the 
selected studies, seven were cross-sectional; only the study 
by Williams et al.11 was longitudinal. The main objective of 
all selected studies was the evaluation of oral complications 
due to chemotherapy in patients with ALL.
The studies by Torres et al.6 and Subramaniam et al.2 
evaluated the incidence of oral manifestations between gen-
ders. In the study by Torres et al.,6 of the 49 children stud-
ied, 26 (53%) were males and 23 (47%) females. In the study 
by Subramaniam et al.,2 of the 58 children, 37 (63.8%) were 
males and 21 (36.2%) females. The authors did not establish 
an association between gender and the frequency of oral 
manifestations. The remaining studies included in this sys-
tematic review did not assess their patients according to 
gender. In all selected studies, the intraoral examination 
was used to establish the diagnosis of oral lesions during 
chemotherapy. 
Of all evaluated studies, only Pels et al.7 reported the 
performance of intraoral clinical examination before the start 
of chemotherapy. Among the variables analyzed by the 
authors were chemotherapy, type of drugs used by 
the children with ALL, use of chlorhexidine gluconate, oral 
hygiene, and place of residence. 
Table 2 Methodology and objectives of the selected studies.
Study Objective
Number of patients / age/ 
study groups.
Oral health assessment
Variables analyzed
(risk factors)
Subramaniam et al. 
(India, 2008)2 
To evaluate 
the oral 
manifestations 
in children 
with ALL during 
chemotherapy
58 (49 in the study group 
and 19 control children), 
age not reported
Performed through 
intraoral examinations
1. Oral health;
2. Compare outcomes 
between the study 
groups;
3. Most common sites of 
oral manifestations;
4. Gender;
5. Chemotherapy phase
Torres et al.  
(Mexico, 2010)6
To determine 
the prevalence 
of oral 
manifestations in 
pediatric patients 
with ALL receiving 
chemotherapy, 
and to evaluate 
risk factors
49 children aged 2 to 14 
years
Performed through 
intraoral examinations
1. Oral health;
2. Gender;
3. Age;
4. Time and type of 
treatment;
5. Chemotherapy phase
Pels and Blaszczak 
(Poland, 2012)7
To assess the 
state of oral 
hygiene in 
children with 
ALL during anti-
cancer treatment
156 (78 in the study group 
and 78 in the control 
group), aged 2 to 18 years
Intraoral examination 
(simplified oral 
hygiene index (OHI-S)/
plaque index and 
gingival index). 
Period of examinations:
First test: one month 
before chemotherapy;
Second test: one to five 
months after the start 
of treatment;
Third test: six to 18 
months of treatment
1. Oral hygiene;
2. Gingival disease;
3. Compare outcomes 
between the study 
groups;
4. Treatment used
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Table 2 Methodology and objectives of the selected studies (cont.).
Study Objective
Number of patients / age/ 
study groups.
Oral health assessment
Variables analyzed
(risk factors)
Sonis et al.  
(USA, 1995)8
To evaluate the 
prevalence of dental 
caries and periodontal 
disease in children 
with ALL, comparing 
three treatment 
modalities
64 children: first group 
(chemotherapy), Second 
group (chemotherapy 
associated with 1,800 
cranial cGy), Third group 
(chemotherapy combined 
with 2,400 cranial cGy). 
Age < 5 years
Performed through 
intraoral examinations. 
(DMF-T, OHI-M, IG-M)
1. Oral health;
2. Dental caries;
3. Bacterial plaque;
4. Gingival disease;
5. Compare outcomes 
between the study groups;
6. Treatment used
Pinto et al.  
(Brazil, 2006)9
To evaluate the 
clinical aspects 
of oral mucosa in 
children with ALL 
and determine 
the effect of 
chlorhexidine 0.12% 
in the prevention of 
oral complications in 
these patients
33 children. Group I (23 
children): oral solution 
of chlorhexidine 0.12%, 
twice a day; Group II (ten 
children): did not receive 
this solution. Aged 2 to 15 
years
Clinical examination 
of the oral cavity/
digital palpation of 
the oral mucosa, 
and cytological 
smears (obtained 
from the oral mucosa 
at the beginning 
of chemotherapy 
intensification)
1. Presence of mucositis;
2. Effects of chlorhexidine 
0.12%;
3. Compare outcomes 
between the study groups
Soares et al. 
(Brazil, 2011)10
Evaluation of changes 
in the oral mucosa 
and qualitative 
alterations of the 
microbiota in children 
with ALL undergoing 
chemotherapy
17 children, aged 2 to 12 
years
Clinical examination 
of the oral mucosa for 
the detection of oral 
lesions
1. Presence of mucositis;
2. Effects of chlorhexidine 
0.12% on oral microbiota
Williams MC. 
(England, 1992)11
To investigate 
the incidence of 
alterations in the oral 
mucosa in a group of 
children during the 
first six months of 
anticancer treatment
24 children (12 children in 
the study group and 12 in 
the control group). Age not 
reported
1. Intraoral 
examination aimed 
at assessing the oral 
manifestations;
1. Oral health;
2. Salivary flow; 2. Amount of saliva;
3. Presence of Candida 
in the oral mucosa;
3. Amount of Candida;
4. Hematological 
examination
4. Number of neutrophils;
5. Compare outcomes 
between the study groups
Mendonça et al. 
(2012, Brazil)12
To evaluate the 
association of HSV-1, 
Candida spp. and 
oral bacteria on 
the severity of oral 
mucositis in children 
with ALL
71 patients, age not 
reported
Oral examinations 
aimed at assessing 
the presence of oral 
manifestations in 
children.
1. Oral health; 
2. Evaluate the presence 
of Candida spp. and the 
severity of mucositis in 
patients with ALL
Although six2,6-9,12 of the eight articles mentioned the 
drugs used for chemotherapy, no clear correlation was es-
tablished between oral complications and type of drug used. 
Pels et al.7 established an association between the phase of 
chemotherapy and oral complications; oral manifestations 
were more common in the induction phase. 
The most frequent oral lesions were mucositis,2,6,9-12 
candidiasis,2,6,12 periodontitis,6-8 and gingivitis.6 The most 
common sites of oral manifestation involvement were the 
oral mucosa and labial mucosa, according to the study by 
Subramaniam et al.2 The oral manifestations and most com-
mon sites of the selected studies are presented in Table 3.
The prevalence of oral manifestations was related 
to patients’ poor oral hygiene6 and antineoplastic treat-
ment;2,8 in the selected studies, no specific drug was relat-
ed to the presence of oral manifestations. Another import-
ant factor related to oral manifestations was the quality 
of life and social class of the patients with ALL,6 as the 
presence of HVS and Candida spp. was associated with in-
creasing severity of mucositis in children with ALL.12 
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Table 3 Outcomes obtained from the studies selected in the search.
Study
Most frequently found oral 
manifestations in the study group
Most frequent sites of 
oral manifestations
Outcomes obtained
Subramaniam et al.  
(India, 2008)2
Mucositis (20.6%) - most 
common;
Ulcerations (5.2%);
Candidiasis (3.5%);
Jugal mucosa, 20 (34.4%);
Labial mucosa, 14 (24.1%);
Tongue, 13 (22.4%);
Palate, four (6.9%)
All children undergoing chemotherapy 
showed oral manifestations more 
frequently when compared to children 
in the control group. Oral manifestations 
are more common in the induction phase.
Torres et al.  
(Mexico, 2010)6
Gingivitis, 91.84%;
Caries, 81.63%;
Mucositis, 38.77%;
Periodontitis, 16.32%;
Cheilitis, 18.36%;
Repeated herpes, 12.24%;
Gengivostomatitis, 2.04%;
Other manifestations: dry 
mouth, mucosal pallor, mucosal 
petechiae, and ulcers/oral 
candidiasis, 6.12%
Not mentioned in  
the study
It was observed that ALL combined 
with poor oral hygiene are important 
risk factors for the development of 
candidiasis and gingivitis
Pels and Blaszczak 
(Poland, 2012)7
The gingival index was higher in 
children with ALL compared to 
control children
Not mentioned in  
the study
Although children with ALL had better 
oral hygiene, higher rates of gingival 
diseases were observed in children with 
ALL, compared to control children
Sonis, AL et al.  
(USA, 1995)8
There was no difference in the 
prevalence of dental caries 
among children in the control 
group and the test group. 
Patients who received 2,400 
cGy presented higher risk of 
developing periodontal disease 
when compared to the control 
group
Not mentioned in  
the study
The results of this study suggest 
that children with ALL treated with 
chemotherapy did not have a higher risk 
of developing caries. There was a higher 
risk of developing periodontal disease 
among children from the test group
Pinto et al.  
(Brazil, 2006)9
Mucositis was observed in six 
children from Group I and in 
eight from Group II, and was 
characterized by the presence 
of edema, erythema, and ulcers
Not mentioned in  
the study
Chlorhexidine showed to be beneficial in 
the reduction of oral manifestations in 
children
Soares et al.  
(Brazil, 2011)10
Mucositis was the most common 
oral manifestation, affecting 
five children
Not mentioned in  
the study
The prophylactic use of 0.12% 
chlorhexidine gluconate reduces 
the frequency of oral mucositis and 
oral pathogens in children with ALL 
undergoing chemotherapy
Williams  
(England, 1992)11
The main oral manifestation 
was the presence of ulcerations
Not mentioned in  
the study
The main oral problem was ulceration, 
which was associated with the low 
number of neutrophils
Mendonça et al.  
(2012, Brazil)12
Candidiasis showed to be 
associated with mucositis
Not mentioned in  
the study
The presence of HSV and Candida spp. 
is associated with increasing severity of 
mucositis in children with ALL
Discussion
The selected studies in this systematic review evaluated 
the oral manifestations in patients with ALL. The studies 
by Torres et al.6 and by Subramaniam et al.2 estimated the 
incidence between genders, but did not establish an associ-
ation between gender and frequency of oral manifestations; 
no other study showed such association. 
In the study by Subramaniam et al.,2 oral manifestations 
were observed in 77.8%, 36.4%, 70%, and 66.7% of children, 
divided according to the groups in the study. In the study by 
Torres et al.,6 approximately 95% of patients had some type 
of oral manifestation. These results corroborate the findings 
from other studies.13,14
Chemotherapy can be directly toxic and affect the 
oral mucosa through the systemic circulation. Moreover, 
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the drugs used are often secreted through the saliva, 
which results in drug exposure in the oral cavity.15 How-
ever, among the studies selected, only six2,6-9,12 men-
tioned the drug combinations used in chemotherapy, and 
none directly correlated the oral manifestations to a spe-
cific type of drug. 
Among the drugs most often associated with oral man-
ifestations, teniposide, paclitaxel, methotrexate, idarubi-
cin, epirubicin, doxorubicin, cisplatin, and cytarabine are 
associated with mucositis, xerostomia, gingival bleeding, 
and other diseases of the oral cavity.16,17 Methotrexate, 
bleomycin, doxorubicin, cisplatin, vinblastine and vincris-
tine are drugs that produce direct toxicity of some of their 
antimetabolites and other synthetic agents, such as hy-
droxyurea and procarbazine hydrochloride, which lead to 
glandular degeneration, changes in collagen, and epithelial 
dysplasia.15,18 Drug combinations used during chemotherapy 
in the studies are shown in Table 4. 
Mucositis was the most common oral manifestation in 
the study by Subramaniam et al.,2 affecting 20.6% of pa-
tients with leukemia, whereas among children who were not 
undergoing treatment, only 3.4% had mucositis. For most 
researchers, mucositis is caused by chemotherapy and oc-
curs due to a dynamic process, resulting in the destruction 
of the basal cells; the same is stated by Sonis,19 in a study 
published in 1998, who also mentioned that tissue dam-
age was caused by direct contact with the antineoplastic 
agents. In the study by Torres et al.,6 mucositis was not the 
most frequent disease; nevertheless, it affected approxi-
mately 38.7% of children. 
In the study by Pels et al.,7 although children with ALL 
had better oral hygiene, they had more oral manifestations 
than children from the comparison group; oral mucositis 
was the most common lesion among patients undergoing 
chemotherapy. Pinto et al.9 concluded that good oral hy-
giene associated with the use of 0.12% chlorhexidine glu-
Table 4 Chemotherapeutic drugs used and phases of chemotherapy.
Study Chemotherapeutic drugs used Phases of chemotherapy
Subramaniam et al. 
(India, 2008)2
Induction therapy - daunorubicin 30 mg, vincristine 1.4 mg, 
L-asparaginase, methotrexate 12 mg
Four phases
Induction therapy with radiotherapy - mercaptopurine 75 mg, 
cyclophosphamide 750 mg, methotrexate 12 mg
Repetition - daunorubicin 30 mg, vincristine 1.4 mg, L-asparaginase 6000 
U, methotrexate 12 mg
Consolidation - mercaptopurine 75 mg, cyclophosphamide 750 mg, 
vincristine 14 mg, cytarabine
Maintenance – vincristine 1.4 mg, methotrexate 15 mg, L-asparaginase 
6000 u, daunorubicin 30 mg, prednisolone 40 mg
Torres et al. 
(Mexico, 2010)6
All patients were treated according to the chemotherapy protocol used 
and time of treatment:
Three phases
Zero to seven weeks - doxorubicin, vincristine, prednisone, 
L-asparaginase, and methotrexate
Seven to 14 weeks –high doses of methotrexate, dexamethasone, 
cytosine arabinose, cytarabine, and cyclophosphamide
14 weeks to 3 years - methotrexate, 6-mercaptopurine, 
cyclophosphamide, cytarabine, or a combined therapy: prednisone, 
vincristine, and cytosine arabinose
Pels and Blaszczak 
(Poland, 2012)7
The Berlin-Frankfurt-Münster protocol was used13 Not mentioned
Sonis et al.  
(USA, 1995)8
Chemotherapy protocols were used in the treatment according to the 
neoplasia stage14,15
Three phases
Pinto et al.  
(Brazil, 2006)9
The protocol proposed by the Brazilian Society of Pediatric Oncology 
for the treatment of acute leukemia was used.16 Methotrexate was 
one of the drugs used in this therapy. Chlorhexidine gluconate 0.12% 
was administered for ten consecutive days after each infusion of 
methotrexate during chemotherapy intensification
Not mentioned
Soares et al. 
(Brazil, 2011)10
Not mentioned Not mentioned
Williams  
(England, 1992)11
Not mentioned Not mentioned
Mendonça et al. 
(Brazil, 2012)12
The protocol for the treatment of acute leukemia proposed by the 
Brazilian Society of Pediatric Oncology was used16
Not mentioned
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conate prevented oral manifestations in children with ALL, 
especially mucositis, due to its capacity to interfere with 
microorganism adhesion, when used as an antiseptic in the 
oral cavity.
The study by Soares et al.10 showed similar results to 
the study of Pinto et al.9 children who used chlorhexidine 
gluconate had fewer oral manifestations when compared to 
the control group. A microbiological analysis showed a re-
duction in pathogenic microorganisms in the oral cavity, and 
mucositis, the most frequent oral manifestation, was ob-
served in five children (29.4% of the sample). Other studies 
also evaluated the use of chlorhexidine in patients with ALL, 
with positive results in reducing oral manifestations caused 
by chemotherapy.20,21
In the study by Torres et al.,6 the most common oral 
manifestation was gingivitis, affecting 91.84% of the sam-
ple; the high rate of gingivitis in this study was associated to 
poor oral hygiene, in addition to chemotherapy. The chemo-
therapy phase also showed an association with the onset of 
gingivitis. In the study by Subramaniam et al.,2 the rate 
of gingivitis was lower: less than 2% among patients. This 
difference may be due to the better oral hygiene of the chil-
dren participating in that study,2 corroborating the findings 
of Trindade et al.,14 who demonstrated that oral hygiene 
should be encouraged at any stage of treatment, since it 
can prevent oral and systemic manifestations. 
The study by Sonis et al.8 concluded that patients with ALL 
treated with chemotherapy had the same probability of den-
tal caries as children from the control group. For the authors, 
the presence of caries was associated with poor oral hygiene 
of the participants. These results corroborate the findings of 
Sepet et al.,22 who assessed the presence of caries among 
children in the maintenance phase of chemotherapy and in a 
group of healthy children, observing no correlation between 
the presence of caries and the use of chemotherapeutic drugs. 
Primary herpetic gingivostomatitis was observed in 
2.04% of the patients in the study by Torres et al.,6 and 
recurrent herpes in 12.24% . The presence of herpes in that 
study could have been caused by the participants’ low im-
munity, associated with exposure to the virus; this result 
corroborates other studies that also reported the presence 
of herpetic stomatitis in children with ALL.23,24
In the longitudinal study by Williams et al.,11 all patients 
had ulcerations in the oral mucosa, whereas oral candidiasis 
was observed in 10% of tests performed during the study 
period. The presence of the disease was associated with the 
low number of neutrophils of leukemia patients in combina-
tion with low salivary flow caused by chemotherapy. In the 
study by Mendonça et al.,12 oral candidiasis was also associ-
ated with the presence and severity of mucositis; antifungal 
prophylaxis was suggested in patients with ALL with muco-
sitis. This same suggestion was made in the study by Pine et 
al., published in 2010.25 Other oral manifestations observed 
in these studies were dry mouth, gingival bleeding, oral er-
ythema, toothache, and primary herpetic stomatitis.
Conclusion
The oral health status of patients with ALL varies according 
to a number of factors. The results of the studies demon-
strated that most patients with ALL had some lesion in the 
oral cavity during or after the start of chemotherapy. The 
dentist is responsible for recognizing these lesions and inter-
vening in the oral health of these patients, thereby contrib-
uting to their treatment and quality of life improvement. 
New studies are required to better elucidate the subject, 
especially regarding the prevention and control of these 
oral manifestations. 
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